CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 230 target
Drug / intervention
LBL-024 for Injection +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06783647
NCT06783647Phase 2RecruitingOn Track
CompareCT.gov

An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 01(NSCLC)]

Nanjing Leads Biolabs Co.,Ltd·interventional·Posted Jan 20, 2025·Updated May 18, 2026

In Brief

A Phase 2 clinical trial evaluating LBL-024 for Injection, Docetaxel Injection, and 4 other interventions for Advanced Solid Tumour. Currently recruiting, targeting 230 participants across 24 sites.

Detailed Summary

An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumour
CountriesChina
CollaboratorsSun Yat-Sen University Cancer Center

Timeline

Phase 2Recruiting
202520262027
First PostedJan 20, 2025
Enrollment StartJun 11, 2025
Primary CompletionDec 24, 2026
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 1.4 years agoPrimary completion in 6 months

Interventions

LBL-024 for Injectiondrug

intravenous infusion.

Docetaxel Injectiondrug

intravenous infusion.

Bevacizumab Injectiondrug

intravenous infusion.

Pemetrexed Disodium for Injectiondrug

intravenous infusion.

Paclitaxel Injectiondrug

intravenous infusion.

Carboplatin Injectiondrug

intravenous infusion.